Page last updated: 2024-12-06
morazone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
morazone: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 39609 |
| CHEMBL ID | 2105072 |
| CHEBI ID | 135584 |
| SCHEMBL ID | 25200 |
| MeSH ID | M0054031 |
Synonyms (45)
| Synonym |
|---|
| 1,2-dihydro-1,5-dimethyl-4-((3-methyl-2-phenyl-4-morpholinyl)methyl)-2-phenyl-3h-pyrazol-3-one |
| einecs 229-447-1 |
| antipyrine, 4-((3-methyl-2-phenylmorpholino)methyl)- |
| nsc 292156 |
| 4-((3-methyl-2-phenylmorpholino)methyl)antipyrine |
| morazonum [inn-latin] |
| 3-pyrazolin-5-one, 2,3-dimethyl-4-(3-methyl-2-phenylmorpholino)methyl-1-phenyl- |
| 3h-pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-4-((3-methyl-2-phenyl-4-morpholinyl)methyl)-2-phenyl- |
| brn 0347917 |
| morazona [inn-spanish] |
| nsc292156 |
| 4-[(3-methyl-2-phenylmorpholino)methyl]antipyrine |
| tarugan |
| morazone |
| 3h-pyrazol-3-one,2-dihydro-1,5-dimethyl-4-[(3-methyl-2-phenyl-4-morpholinyl)methyl]-2-phenyl- |
| novartrina |
| 6536-18-1 |
| antipyrine, 4-[(3-methyl-2-phenylmorpholino)methyl]- |
| 3-pyrazolin-5-one,3-dimethyl-4-(3-methyl-2-phenylmorpholino)methyl-1-phenyl- |
| wln: t6n dotj b1 cr& a1- dt5nnvj a1 br e1 |
| 4-(2'-phenyl-3'-methylmorpholinomethyl)-1-phenyl-2,3-dimethyl-3-pyrazoline-5-one |
| r 445 |
| nsc-292156 |
| orsimon |
| CHEBI:135584 |
| 1,5-dimethyl-4-[(3-methyl-2-phenylmorpholin-4-yl)methyl]-2-phenylpyrazol-3-one |
| CHEMBL2105072 |
| unii-870q5bl2fn |
| morazone [inn:ban] |
| morazona |
| morazonum |
| 870q5bl2fn , |
| morazone [inn] |
| morazone [who-dd] |
| morazone [mi] |
| SCHEMBL25200 |
| OOGNFQMTGRZRAB-UHFFFAOYSA-N |
| 3h-pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-4-[(3-methyl-2-phenyl-4-morpholinyl)methyl]-2-phenyl- |
| 4-[(3-methyl-2-phenyl-4-morpholino)methyl]antipyrine |
| 1,5-dimethyl-4-[(3-methyl-2-phenyl-4-morpholinyl)methyl]-2-phenyl-1,2-dihydro-3h-pyrazol-3-one # |
| 1,5-dimethyl-4-((3-methyl-2-phenylmorpholino)methyl)-2-phenyl-1,2-dihydro-3h-pyrazol-3-one |
| 4-bromo-4-p-tolylpiperidine hydrobromide |
| Q6909468 |
| DTXSID10863901 |
| AKOS040747181 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| morpholines | Any compound containing morpholine as part of its structure. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.69
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.69) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (16.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||